Late Scan Time-point Optimalisation of 18F-Fluoroestradiol for the Large Field-of-view (LAFOV) PET/CT Scanner.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07627269

Enrollment

Registered

2026-06-04

Start date

2026-06-01

Completion date

2030-08-01

Last updated

2026-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Currently, in routine patient care PET/CT scan protocols used on high sensitivity large field of-view (LAFOV) PET/CT systems are based on protocols that historically were developed for standard field-of-view (SAFOV) PET/CT systems with a much lower sensitivity profile. In the current SAFOV-based imaging protocols, the maximum delay between injection and actual scanning is limited by increasing noise (due to radioactive decay) resulting in bad image quality. A major advantage of later time-point imaging in general is, that the target-to background ratio improves. With the high-sensitive LAFOV PET/CT scanner later time-point imaging becomes possible, and higher tumour-to background ratios can be obtained. Specifically for the 18F-Fluoroesradiol tracer, used to image estrogen receptor positive tumors, high physiological uptake in the liver and intestines hampers the visualization and quantification of liver metastases and peritoneal metastases. The aim of this study is to evaluate whether late time point imaging with the 18F-Fluoroestradiol tracer on the LAFOV PET/CT improves visualization and quantification of liver metastases and peritoneal metastases.

Interventions

RADIATIONLate scan time-point(s) optimalisation of 89Zr trastuzumab18F-Fluoroestradiol

Patients who consent in participating will be scanned at one to two additional time-point(s) after injection, at a time-point that is later than the one currently used in practice.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are referred for PET/CT imaging with 18F-Fluoroestradiol will be included in this study.

Exclusion criteria

* Patients who are not able to lay down in supine position for up to one hour.

Design outcomes

Primary

Measure	Time frame
The primary outcome measure is the sensitivity/specificity of FES PET for liver metastases and peritoneal metastases, using conventional CT as gold standard.	Day 1

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 5, 2026